EP2403852B8 - 2-aminobenzimidazole-5-carboxamides en tant qu'anti-inflammatoires - Google Patents
2-aminobenzimidazole-5-carboxamides en tant qu'anti-inflammatoires Download PDFInfo
- Publication number
- EP2403852B8 EP2403852B8 EP10706659.9A EP10706659A EP2403852B8 EP 2403852 B8 EP2403852 B8 EP 2403852B8 EP 10706659 A EP10706659 A EP 10706659A EP 2403852 B8 EP2403852 B8 EP 2403852B8
- Authority
- EP
- European Patent Office
- Prior art keywords
- aminobenzimidazole
- carboxamides
- inflammatory agents
- inflammatory
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MEP-2015-11A ME02117B (me) | 2009-03-05 | 2010-03-05 | 2-aminobenzimidazol-5-karboksamidi kao anti-inflamatorni agensi |
| PL10706659T PL2403852T3 (pl) | 2009-03-05 | 2010-03-05 | 2-aminobenzoimidazolo-5-karboksyamidy jako środki przeciwzapalne |
| EP10706659.9A EP2403852B8 (fr) | 2009-03-05 | 2010-03-05 | 2-aminobenzimidazole-5-carboxamides en tant qu'anti-inflammatoires |
| SI201030855T SI2403852T1 (sl) | 2009-03-05 | 2010-03-05 | 2-aminobenzimidazol-5-karboksamidi kot protivnetna sredstva |
| HRP20150096AT HRP20150096T1 (hr) | 2009-03-05 | 2015-01-26 | 2-aminobenzimidazol-5-karboksamidi kao protuupalni agensi |
| CY20151100083T CY1115959T1 (el) | 2009-03-05 | 2015-01-27 | 2-αμινοβενζιμιδαζολο-5-καρβοξαμιδιο ως αντι-φλεγμονωδεις παραγοντες |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09154414 | 2009-03-05 | ||
| EP09179618 | 2009-12-17 | ||
| PCT/EP2010/052799 WO2010100249A1 (fr) | 2009-03-05 | 2010-03-05 | 3h-imidazo[4,5-c]pyridine-6-carboxamides en tant qu'anti-inflammatoires |
| EP10706659.9A EP2403852B8 (fr) | 2009-03-05 | 2010-03-05 | 2-aminobenzimidazole-5-carboxamides en tant qu'anti-inflammatoires |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP2403852A1 EP2403852A1 (fr) | 2012-01-11 |
| EP2403852B1 EP2403852B1 (fr) | 2014-10-29 |
| EP2403852B8 true EP2403852B8 (fr) | 2014-12-17 |
Family
ID=42111729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10706659.9A Active EP2403852B8 (fr) | 2009-03-05 | 2010-03-05 | 2-aminobenzimidazole-5-carboxamides en tant qu'anti-inflammatoires |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US20100256188A1 (fr) |
| EP (1) | EP2403852B8 (fr) |
| JP (1) | JP5433708B2 (fr) |
| KR (1) | KR20110123764A (fr) |
| CN (1) | CN102341395B (fr) |
| AP (1) | AP2806A (fr) |
| AR (1) | AR075789A1 (fr) |
| AU (1) | AU2010220263B2 (fr) |
| BR (1) | BRPI1009118A2 (fr) |
| CA (1) | CA2753149A1 (fr) |
| CL (1) | CL2011002180A1 (fr) |
| CO (1) | CO6450668A2 (fr) |
| CY (1) | CY1115959T1 (fr) |
| DK (1) | DK2403852T3 (fr) |
| EA (1) | EA020282B1 (fr) |
| EC (1) | ECSP11011324A (fr) |
| ES (1) | ES2528730T3 (fr) |
| GE (1) | GEP20146034B (fr) |
| HK (1) | HK1163064A1 (fr) |
| HR (1) | HRP20150096T1 (fr) |
| IL (1) | IL214033A0 (fr) |
| MA (1) | MA33239B1 (fr) |
| ME (1) | ME02117B (fr) |
| MX (1) | MX2011008948A (fr) |
| MY (1) | MY161092A (fr) |
| NZ (1) | NZ594589A (fr) |
| PE (1) | PE20120589A1 (fr) |
| PL (1) | PL2403852T3 (fr) |
| PT (1) | PT2403852E (fr) |
| RS (1) | RS53757B1 (fr) |
| SG (1) | SG174250A1 (fr) |
| SI (1) | SI2403852T1 (fr) |
| SM (1) | SMT201500053B (fr) |
| TN (1) | TN2011000446A1 (fr) |
| TW (1) | TWI466869B (fr) |
| UY (1) | UY32470A (fr) |
| WO (1) | WO2010100249A1 (fr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| US8586604B2 (en) * | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8759537B2 (en) * | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| UY33779A (es) * | 2010-12-10 | 2012-07-31 | Boehringer Ingelheim Int | ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas? |
| US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| AR084174A1 (es) | 2010-12-21 | 2013-04-24 | Lilly Co Eli | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| WO2013038308A1 (fr) | 2011-09-15 | 2013-03-21 | Glenmark Pharmaceuticals S.A. | Composés à base d'hétéroaryle bicyclique substitué capables d'inhiber mpges-1 |
| PT2766359T (pt) * | 2011-10-14 | 2016-07-14 | Ambit Biosciences Corp | Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii |
| WO2013072825A1 (fr) | 2011-11-16 | 2013-05-23 | Glenmark Pharmaceuticals S.A. | Dérivés de phtalazinone en tant qu'inhibiteurs de mpges-1 |
| US9006257B2 (en) | 2012-02-09 | 2015-04-14 | Glenmark Pharmaceuticals S.A. | Bicyclic compounds as mPGES-1 inhibitors |
| US9580398B2 (en) * | 2012-04-02 | 2017-02-28 | The Trustees Of Columbia University In The City Of New York | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders |
| WO2013153535A1 (fr) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Composés tricycliques à titre d'inhibiteurs de la mpges-1 |
| CN103450329B (zh) * | 2012-05-29 | 2015-05-27 | 首都医科大学 | 3h-咪唑并吡啶-6-甲酰氨基酸苄酯、其合成、抗肿瘤活性和应用 |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2014167444A1 (fr) | 2013-04-08 | 2014-10-16 | Glenmark Pharmaceuticals S.A. | Composés bicycliques substitués utilisés en tant qu'inhibiteurs de mpges-1 |
| CA2916071A1 (fr) * | 2013-06-20 | 2014-12-24 | Novasaid Ab | Nouveaux derives piperidinyle benzoimidazole utilises comme inhibiteurs de la mpges-1 |
| WO2015059618A1 (fr) | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | Composés de pyrimidine substitués utilisés en tant qu'inhibiteurs de mpges-1 |
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| PE20170143A1 (es) | 2014-02-11 | 2017-03-19 | Bayer Pharma AG | Benzimidazol-2-aminas como inhibidores de midh1 |
| CN105294829B (zh) * | 2014-06-13 | 2018-07-27 | 首都医科大学 | 咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性及应用 |
| CN105198959B (zh) * | 2014-06-13 | 2018-09-07 | 首都医科大学 | 咪唑并吡啶-6-甲酰-Met-Glu(OBzl)2,其合成,活性和应用 |
| CN105198960B (zh) * | 2014-06-13 | 2018-10-19 | 首都医科大学 | 咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用 |
| CN105315325A (zh) * | 2014-07-10 | 2016-02-10 | 首都医科大学 | 咪唑并吡啶-6-甲酰-Met-Arg(NO2)-OBzl,其合成,活性和应用 |
| CN105315335A (zh) * | 2014-07-10 | 2016-02-10 | 首都医科大学 | 咪唑并吡啶-6-甲酰-Met-Gln-OBzl,其合成,活性和应用 |
| CN105315326A (zh) * | 2014-07-10 | 2016-02-10 | 首都医科大学 | 咪唑并吡啶-6-甲酰-氨基酸苄酯,合成,活性和应用 |
| PT3174535T (pt) | 2014-08-01 | 2019-05-27 | Glenmark Pharmaceuticals Sa | Formulação nanoparticulada compreendendo um inibidor de mpges-1 |
| EP3209660B1 (fr) | 2014-10-23 | 2020-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 1-cyclohexyl -2-phénylaminobenzimidazoles en tant qu'inhibiteurs de midh1 dans le traitement de tumeurs |
| JP6783756B2 (ja) | 2014-10-23 | 2020-11-11 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン |
| AR102361A1 (es) | 2014-10-29 | 2017-02-22 | Lilly Co Eli | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
| JO3581B1 (ar) * | 2014-10-29 | 2020-07-05 | Lilly Co Eli | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
| US10370339B2 (en) | 2015-06-08 | 2019-08-06 | Bayer Pharma Aktiengesellschaft | N-Methylbenzimidazoles as mIDH1 inhibitors |
| JP6824954B2 (ja) | 2015-07-16 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール |
| GB201603311D0 (en) * | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
| EP3713564B1 (fr) | 2017-11-22 | 2023-11-15 | Khondrion Ip B.V. | Composés utilisés en tant qu'inhibiteurs de mpges-1 |
| EP3990476A1 (fr) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
| EP4023638A4 (fr) * | 2019-08-26 | 2023-10-04 | Kukje Pharma Co., Ltd. | Dérivé d'indole carboxamide et composition pharmaceutique le contenant |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
| US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
| CR20220547A (es) | 2020-05-01 | 2022-12-15 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 |
| WO2021226261A1 (fr) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-hétéroaryloxy benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
| US20220378771A1 (en) * | 2021-05-25 | 2022-12-01 | Louis Habash | Modifying the expression level of a gene encoding an cyclooxygenase enzyme by treating a human subject with a nitroxide |
| EP4359415A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
| WO2022271650A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CA3222439A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes modulant les diacylglycerol kinases |
| CA3235986A1 (fr) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Composes cd73 |
| AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Ｋｒａｓ ｇ１２ｄ調節化合物 |
| WO2024006929A1 (fr) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Composés cd73 |
| WO2024064668A1 (fr) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3006671A1 (de) | 1980-02-22 | 1981-08-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue benzoxazole, deren herstellung und deren verwendung als arzneumittel |
| FI91859C (fi) | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
| JPH06759B2 (ja) | 1989-09-22 | 1994-01-05 | ファイザー製薬株式会社 | 新規なベンゾイミダゾール化合物 |
| KR20010085630A (ko) | 1998-08-26 | 2001-09-07 | 앤드류 앵뉴 | 세포 접착 억제를 조절하는 아자-비사이클 |
| ES2263447T3 (es) * | 1999-02-16 | 2006-12-16 | Aventis Pharma Limited | Compuestos biciclicos y su uso como ligandos en los receptores de integrinas. |
| SK14372001A3 (sk) * | 1999-04-12 | 2002-06-04 | Aventis Pharma Limited | Substituované bicyklické heteroarylové zlúčeniny ako antagonisty integrínu a farmaceutický prostriedok, ktorý ich obsahuje |
| CA2372840C (fr) * | 1999-05-05 | 2008-07-22 | Aventis Pharma Limited | Composes bicycliques substitues |
| US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| ATE277044T1 (de) * | 1999-10-06 | 2004-10-15 | Boehringer Ingelheim Pharma | Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren |
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| CA2477505A1 (fr) | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines et leurs utilisations en tant qu'inhibiteurs de l'angiogenese |
| US7071216B2 (en) | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| US7122665B2 (en) | 2002-10-15 | 2006-10-17 | Synta Pharmaceuticals Corp. | Heterocyclic compounds |
| US7265138B2 (en) | 2003-02-10 | 2007-09-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| FR2851563B1 (fr) * | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| FR2852957B1 (fr) * | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament |
| US7329682B2 (en) * | 2003-04-03 | 2008-02-12 | Ewha University-Industry Collaboration Foundation | Method for inhibiting 5-lipoxygenase using a benzoxazole derivative |
| EP1677791A4 (fr) | 2003-10-31 | 2007-08-15 | Takeda Pharmaceutical | Composes heterocycliques accoles contenant de l'azote |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| US20080188473A1 (en) | 2004-06-18 | 2008-08-07 | Kristofer Olofsson | Indoles Useful in the Treatment of Inflammation |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| CN101142185A (zh) * | 2005-01-19 | 2008-03-12 | 比奥里波克斯公司 | 用于炎症治疗的吲哚 |
| CA2599320A1 (fr) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Composes |
| US7820821B2 (en) * | 2006-02-10 | 2010-10-26 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
| WO2007124589A1 (fr) | 2006-05-02 | 2007-11-08 | Merck Frosst Canada Ltd. | Procédés permettant de traiter ou de prévenir des néoplasies |
| WO2008009924A2 (fr) * | 2006-07-18 | 2008-01-24 | Biolipox Ab | Indoles utiles dans le traitement de l'inflammation |
| WO2008035956A1 (fr) | 2006-09-22 | 2008-03-27 | Ewha University - Industry Collaboration Foundation | Nouveau dérivé de benzoxazole, son procédé de préparation et composition pharmaceutique le renfermant |
| WO2008071944A1 (fr) * | 2006-12-14 | 2008-06-19 | Boehringer Ingelheim International Gmbh | Benzoxasoles utiles dans le traitement de l'inflammation |
| WO2008129276A1 (fr) | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides utiles dans le traitement de l'inflammation |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| UY33779A (es) | 2010-12-10 | 2012-07-31 | Boehringer Ingelheim Int | ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas? |
| US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
-
2010
- 2010-03-03 UY UY0001032470A patent/UY32470A/es not_active Application Discontinuation
- 2010-03-04 US US12/717,407 patent/US20100256188A1/en not_active Abandoned
- 2010-03-04 TW TW99106302A patent/TWI466869B/zh not_active IP Right Cessation
- 2010-03-04 AR ARP100100651A patent/AR075789A1/es unknown
- 2010-03-05 ES ES10706659.9T patent/ES2528730T3/es active Active
- 2010-03-05 WO PCT/EP2010/052799 patent/WO2010100249A1/fr active Application Filing
- 2010-03-05 CN CN201080010352.5A patent/CN102341395B/zh not_active Expired - Fee Related
- 2010-03-05 EP EP10706659.9A patent/EP2403852B8/fr active Active
- 2010-03-05 PT PT107066599T patent/PT2403852E/pt unknown
- 2010-03-05 EA EA201101243A patent/EA020282B1/ru not_active IP Right Cessation
- 2010-03-05 ME MEP-2015-11A patent/ME02117B/me unknown
- 2010-03-05 MY MYPI2011004122A patent/MY161092A/en unknown
- 2010-03-05 SI SI201030855T patent/SI2403852T1/sl unknown
- 2010-03-05 AU AU2010220263A patent/AU2010220263B2/en not_active Ceased
- 2010-03-05 MA MA34131A patent/MA33239B1/fr unknown
- 2010-03-05 NZ NZ594589A patent/NZ594589A/en not_active IP Right Cessation
- 2010-03-05 PL PL10706659T patent/PL2403852T3/pl unknown
- 2010-03-05 GE GEAP201012405A patent/GEP20146034B/en unknown
- 2010-03-05 MX MX2011008948A patent/MX2011008948A/es active IP Right Grant
- 2010-03-05 JP JP2011552460A patent/JP5433708B2/ja active Active
- 2010-03-05 BR BRPI1009118A patent/BRPI1009118A2/pt not_active IP Right Cessation
- 2010-03-05 RS RS20150066A patent/RS53757B1/en unknown
- 2010-03-05 AP AP2011005807A patent/AP2806A/xx active
- 2010-03-05 CA CA2753149A patent/CA2753149A1/fr not_active Abandoned
- 2010-03-05 SG SG2011063765A patent/SG174250A1/en unknown
- 2010-03-05 DK DK10706659.9T patent/DK2403852T3/en active
- 2010-03-05 PE PE2011001560A patent/PE20120589A1/es not_active Application Discontinuation
- 2010-03-05 KR KR1020117020598A patent/KR20110123764A/ko not_active Application Discontinuation
-
2011
- 2011-07-12 IL IL214033A patent/IL214033A0/en unknown
- 2011-09-02 TN TN2011000446A patent/TN2011000446A1/fr unknown
- 2011-09-05 CL CL2011002180A patent/CL2011002180A1/es unknown
- 2011-09-12 CO CO11117866A patent/CO6450668A2/es active IP Right Grant
- 2011-09-13 EC EC2011011324A patent/ECSP11011324A/es unknown
-
2012
- 2012-04-03 HK HK12103284.5A patent/HK1163064A1/xx not_active IP Right Cessation
- 2012-04-06 US US13/441,085 patent/US20120196897A1/en not_active Abandoned
-
2013
- 2013-07-15 US US13/942,077 patent/US8921405B2/en active Active
-
2015
- 2015-01-26 HR HRP20150096AT patent/HRP20150096T1/hr unknown
- 2015-01-27 CY CY20151100083T patent/CY1115959T1/el unknown
- 2015-03-09 SM SM201500053T patent/SMT201500053B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20182200T1 (hr) | Nova protuupalna sredstva | |
| EP2403852B8 (fr) | 2-aminobenzimidazole-5-carboxamides en tant qu'anti-inflammatoires | |
| IL230542B (en) | Anti-inflammatory factors | |
| IL211147A0 (en) | 1h-benzimidazole-5-carboxamides as anti-inflammatory agents | |
| EP2518235A4 (fr) | Elements auxiliaires | |
| AU2009100824A4 (en) | Heslr | |
| AU2009100437A4 (en) | Pippetop | |
| AU2009904787A0 (en) | Anti-inflammatory agents | |
| AU2009905498A0 (en) | Anti-inflammatory compounds | |
| AU2010904345A0 (en) | Anti-inflammatory agents | |
| AU2009100848A4 (en) | Headbags | |
| AU2009100564A4 (en) | Agwave | |
| AU2009100680A4 (en) | Ezy-Lay | |
| AU2009100549A4 (en) | XBlend | |
| AU2009100472A4 (en) | Duramind | |
| AU2009101028A4 (en) | Hybridtelerent | |
| AU2009100423A4 (en) | Byak | |
| AU2009100147A4 (en) | Safetank | |
| AU2009100092A4 (en) | Interfilm | |
| AU2009100982A4 (en) | Flip - barbi | |
| AU2009903468A0 (en) | Not Given | |
| AU2009903466A0 (en) | Not Given | |
| AU2009905534A0 (en) | Not Given | |
| AU2009901866A0 (en) | Not Given | |
| AU2009905414A0 (en) | Not Given |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20111005 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA ME RS |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602010019806 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07D0471040000 Ipc: C07D0235300000 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 405/12 20060101ALI20140320BHEP Ipc: C07D 409/12 20060101ALI20140320BHEP Ipc: C07D 401/12 20060101ALI20140320BHEP Ipc: C07D 235/30 20060101AFI20140320BHEP Ipc: C07D 403/12 20060101ALI20140320BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20140523 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PRIEPKE, HENNING Inventor name: LUBRIKS, DIMITRIJS Inventor name: KLINDER, KLAUS Inventor name: ROENN, ROBERT Inventor name: STENKAMP, DIRK Inventor name: ARNDT, KIRSTEN Inventor name: DOODS, HENRI Inventor name: KUELZER, RAIMUND Inventor name: PFAU, ROLAND Inventor name: MACK, JUERGEN Inventor name: PELCMAN, BENJAMIN Inventor name: SUNA, EDGARS |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA ME RS |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 693511 Country of ref document: AT Kind code of ref document: T Effective date: 20141115 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: OREXO AB |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010019806 Country of ref document: DE Effective date: 20141211 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER AND PEDRAZZINI AG, CH |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20150096 Country of ref document: HR Ref country code: DK Ref legal event code: T3 Effective date: 20150121 Ref country code: RO Ref legal event code: EPE |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20150126 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2528730 Country of ref document: ES Kind code of ref document: T3 Effective date: 20150212 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20150096 Country of ref document: HR |
|
| REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E010153 Country of ref document: EE Effective date: 20150128 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Owner name: OREXO AB, SE Effective date: 20150212 |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20150400110 Country of ref document: GR Effective date: 20150220 |
|
| REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20141029 |
|
| REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010019806 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 18562 Country of ref document: SK |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20150730 |
|
| REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E024186 Country of ref document: HU |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20160718 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NO Payment date: 20160727 Year of fee payment: 7 Ref country code: FI Payment date: 20160727 Year of fee payment: 7 Ref country code: MC Payment date: 20160726 Year of fee payment: 7 Ref country code: DK Payment date: 20160721 Year of fee payment: 7 Ref country code: IS Payment date: 20160722 Year of fee payment: 7 Ref country code: IE Payment date: 20160721 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20160726 Year of fee payment: 7 Ref country code: AT Payment date: 20160725 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20160718 Year of fee payment: 7 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20150096 Country of ref document: HR Payment date: 20170305 Year of fee payment: 8 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: EE Payment date: 20170227 Year of fee payment: 8 Ref country code: LT Payment date: 20170227 Year of fee payment: 8 Ref country code: RO Payment date: 20170227 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20170224 Year of fee payment: 8 Ref country code: CZ Payment date: 20170228 Year of fee payment: 8 Ref country code: BG Payment date: 20170313 Year of fee payment: 8 Ref country code: HU Payment date: 20170224 Year of fee payment: 8 Ref country code: LV Payment date: 20170306 Year of fee payment: 8 Ref country code: LU Payment date: 20170227 Year of fee payment: 8 Ref country code: HR Payment date: 20170305 Year of fee payment: 8 Ref country code: SK Payment date: 20170227 Year of fee payment: 8 Ref country code: PL Payment date: 20170228 Year of fee payment: 8 Ref country code: SI Payment date: 20170227 Year of fee payment: 8 Ref country code: SM Payment date: 20170228 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20170225 Year of fee payment: 8 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 693511 Country of ref document: AT Kind code of ref document: T Effective date: 20141029 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20170228 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20161005 Year of fee payment: 7 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20170331 Ref country code: NO Ref legal event code: MMEP |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170305 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20170401 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 693511 Country of ref document: AT Kind code of ref document: T Effective date: 20170305 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170305 Ref country code: NO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170401 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171001 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170305 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171005 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: FP Effective date: 20150128 Ref country code: BE Ref legal event code: MM Effective date: 20170331 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MK Payment date: 20170227 Year of fee payment: 8 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: PBON Ref document number: P20150096 Country of ref document: HR Effective date: 20180305 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170305 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM4D Effective date: 20180305 |
|
| REG | Reference to a national code |
Ref country code: EE Ref legal event code: MM4A Ref document number: E010153 Country of ref document: EE Effective date: 20180331 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20180927 AND 20181005 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180905 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602010019806 Country of ref document: DE Representative=s name: VKK PATENTANWAELTE PARTG MBB, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602010019806 Country of ref document: DE Owner name: GESYNTA PHARMA AB, SE Free format text: FORMER OWNER: OREXO AB, UPPSALA, SE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 |
|
| REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 18562 Country of ref document: SK Effective date: 20180305 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 |
|
| REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20181105 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181006 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180331 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180306 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180306 Ref country code: SM Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181002 Ref country code: HR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: GESYNTA PHARMA AB, SE Free format text: FORMER OWNER: OREXO AB, SE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: GESYNTA PHARMA AB Effective date: 20200319 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230316 Year of fee payment: 14 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230314 Year of fee payment: 14 Ref country code: IT Payment date: 20230320 Year of fee payment: 14 Ref country code: GB Payment date: 20230309 Year of fee payment: 14 Ref country code: DE Payment date: 20230316 Year of fee payment: 14 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230529 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230406 Year of fee payment: 14 Ref country code: CH Payment date: 20230402 Year of fee payment: 14 |